Ex­clu­sive: Cen­trex­ion's knee pain drug fails two PhI­II stud­ies, but ex-Pfiz­er CEO Kindler's biotech might still ask for FDA nod

The lead drug at Cen­trex­ion Ther­a­peu­tics — a biotech helmed by for­mer Pfiz­er CEO Jeff Kindler and chaired by Cel­gene co-founder Sol Bar­er — has flunked a Phase III test in os­teoarthri­tis knee pain, End­points News has learned.

Sol Bar­er

A sec­ond Phase III tri­al for the drug al­so failed to meet its pri­ma­ry end­point, the com­pa­ny con­firmed to End­points. Cen­trex­ion nev­er planned to is­sue a press re­lease dis­clos­ing the failed stud­ies, but does plan to “sub­mit the da­ta for pub­li­ca­tion in a peer re­viewed med­ical jour­nal,” ac­cord­ing to an emailed state­ment from a spokesper­son.

The Boston biotech might al­so still pack­age up the drug’s re­sults and send it to the FDA’s doorsteps. Three pa­tients died in the treat­ment arms across the two tri­als.

It’s a blow to the com­pa­ny’s pipeline, as Cen­trex­ion had tout­ed CN­TX-4975’s po­ten­tial for a mar­ket de­but in 2022, with FDA fast track des­ig­na­tion al­ready in hand, when it thought about go­ing pub­lic in 2018. The IPO nev­er hap­pened de­spite an­oth­er eye to­ward Nas­daq in 2019.

The com­pa­ny has not pro­vid­ed an up­date on its pipeline, fi­nanc­ing or gen­er­al sta­tus since dis­clos­ing it raised $40.5 mil­lion in Oc­to­ber 2020. Cen­trex­ion had at­tempt­ed to qui­et­ly leave be­hind the first Phase III flop, with the on­ly dis­clo­sure com­ing in the form of an up­date on the clin­i­cal­tri­als.gov data­base on April 8. A press re­lease has not been is­sued.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER